ClinicalTrials.gg
CompletedNCT01323270Updated Oct 27, 2022Results posted

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

A Phase 2 interventional study of rLP2086 and Repevax in Meningococcal Vaccine, rLP2086 and Repevax, sponsored by Pfizer. Completed at 36 sites in 3 countries. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
753
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Meningitis by Pfizer — none open to participants now, none under way, none of them phase 3. Meningitis · Pfizer.

Started
2011
the only one that year
Phase 2
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Meningitis by Pfizer, this one is the only one that started in 2011, is the only one in phase 2, and was the 16th registered.

Meningitis

268 studies on the registry are indexed under Meningitis; 28 are open to participants now.

Browse Meningitis studies →

Open to participants now

None of the 16 studies in Meningitis by Pfizer is open now. The open studies under Meningitis, anywhere →

Who these studies take

Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Meningitis by Pfizer as a file.
02

Study summary

This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax. The study will be done in healthy adolescents.

03

Conditions studied

  • Meningococcal Vaccine
  • rLP2086
  • Repevax
  • N Meningitidis Serogroup B
  • Meningitis

Browse trials for

Keywords

  • Healthy adolescents
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study.
  • Parent/legally acceptable representative and/or subjects who are willing and able to comply with scheduled visits, laboratory tests, and other study procedures.
  • Male or female subject aged ≥11 and \<19 years at the time of enrollment.
  • Available for the entire study period and can be reached by telephone.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  • Has received full series of diphtheria, tetanus, and pertussis (DTP)/DTaP vaccines and oral poliomyelitis virus (OPV)/IPV vaccines per country-specific recommendations applicable at the time of receipt.
  • All male and female subjects must agree to practice a form of effective , such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination. For Germany: The phrase sexual abstinence is not applicable, with the understanding that all male and all female subjects of must practice an effective form of contraception during the study.
  • Negative urine pregnancy test for female subjects.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any meningococcal serogroup B vaccine.
  • Vaccination with any diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine within 5 years of the first study vaccination.
  • A previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination with diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  • A known or suspected disease of the immune system or those receiving therapy.
  • History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.
  • Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  • Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.
  • Current chronic use of systemic antibiotics.
  • Participation in other studies during study participation. Participation in purely observational studies is acceptable.
  • Received any drugs, vaccines or devices within 28 days before administration of the first study vaccination.
  • Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
  • Subject is a direct descendant (eg, child, grandchild or other family member) of study site or Pfizer personnel.
  • Subject is pregnant or breastfeeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
753 participants (actual)

Study arms

  • Experimental
    rLP2086

    rLP2086 and Repevax

    Biological: rLP2086 · Biological: Repevax

  • Placebo comparator
    Saline and Repevax

    Saline and Repevax

    Biological: Saline · Biological: Repevax

Interventions

  • BiologicalrLP2086

    Drug pages: MenB-FHbp vaccine · 4CMenB vaccine

    0.5 mL dose, given at 0, 2 and 6 months.

  • BiologicalRepevax

    0.5 mL dose, given at 0 months.

  • BiologicalSaline

    0.5 mL dose, given at 0, 2 and 6 months.

  • BiologicalRepevax

    0.5 mL dose, given at 0 months.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen

    Time frame: 1 month after Vaccination 1

  2. Percentage of Participants With at Least One Adverse Event (AE)

    Time frame: Vaccination 1 up to 1 month after Vaccination 3

Secondary outcomes

  1. Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens

    Time frame: 1 month after Vaccination 1

  2. GMC for Acellular Pertussis Antigens

    Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)

    Time frame: 1 month after Vaccination 1

  3. Geometric Mean Titer (GMT) for Poliomyelitis Antigens

    Time frame: 1 month after Vaccination 1

  4. Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level

    Time frame: 1 month after Vaccination 3

Other outcomes

  1. Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)

    Time frame: Before vaccination 1, 1 month after Vaccination 2, 3

  2. Geometric Mean Fold-Rise (GMFR) for IgG

    Time frame: Before Vaccination 1, 1 month after Vaccination 2, 3

07

Results

Posted Nov 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Started373376
Completed330347
Not completed4329
Withdrew: Withdrawal by subject1910
Withdrew: Protocol violation97
Withdrew: Lost to follow-up46
Withdrew: Adverse event80
Withdrew: Other03
Withdrew: Physician decision02
Withdrew: Not eligible11
Withdrew: Death10
Withdrew: Randomized, but not vaccinated10

Outcome measures

PrimaryPercentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen
Time frame:
1 month after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen
percentage of participantsGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Diphtheria99.499.4
Tetanus100.0100.0
Pertussis toxoid94.796.0
Pertussis filamentous hemagglutinin100.0100.0
Pertussis pertactin100.0100.0
Pertussis fimbrial agglutinogens types 2+397.698.9
Poliovirus type 1100.0100.0
Poliovirus type 2100.0100.0
Poliovirus type 3100.0100.0
Statistical analysis
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: -0.0 · 95% CI -1.6 to 1.5
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: -1.3 · 95% CI -4.7 to 1.9
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: -1.2 · 95% CI -3.6 to 0.8
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
  • Group 1: rLP2086 + Repevax vs Group 2: Saline+Repevax · Percent difference: 0.0 · 95% CI -1.1 to 1.1
SecondaryGeometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens
Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · International Units per milliliter
Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens
International Units per milliliterGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Diphtheria1.4 (1.28 to 1.55)1.5 (1.34 to 1.63)
Tetanus12.3 (11.50 to 13.11)12.4 (11.52 to 13.25)
SecondaryGMC for Acellular Pertussis Antigens

Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · EU/mL
GMC for Acellular Pertussis Antigens
EU/mLGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Pertussis toxoid27.1 (24.45 to 30.07)26.5 (23.95 to 29.38)
Pertussis filamentous hemagglutinin119.4 (111.15 to 128.17)122.9 (115.14 to 131.13)
Pertussis pertactin317.0 (285.64 to 351.80)336.1 (305.82 to 369.30)
Pertussis fimbrial agglutinogens types 2+3339.1 (296.35 to 387.94)364.5 (320.62 to 414.42)
SecondaryGeometric Mean Titer (GMT) for Poliomyelitis Antigens
Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) for Poliomyelitis Antigens
titerGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Poliovirus type 1662.1 (567.36 to 772.67)672.6 (581.87 to 777.55)
Poliovirus type 2840.5 (725.11 to 974.29)995.8 (860.54 to 1152.41)
Poliovirus type 32237.4 (1945.81 to 2572.65)2450.1 (2152.60 to 2788.70)
SecondaryPercentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level
Time frame:
1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level
percentage of participantsGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
PMB80 [A22] 1:16 (N=158, 166)95.619.9
PMB2001 [A56] 1:8 (N=148, 152)100.026.3
PMB2948 [B24] 1:8 (N=157, 170)96.812.9
PMB2707 [B44] 1:8 (N=146, 159)81.58.2
Other pre-specifiedImmunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)
Time frame:
Before vaccination 1, 1 month after Vaccination 2, 3

No measurements were reported for this outcome.

Other pre-specifiedGeometric Mean Fold-Rise (GMFR) for IgG
Time frame:
Before Vaccination 1, 1 month after Vaccination 2, 3

No measurements were reported for this outcome.

PrimaryPercentage of Participants With at Least One Adverse Event (AE)
Time frame:
Vaccination 1 up to 1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event (AE)
percentage of participantsGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
Percentage of Participants With at Least One Adverse Event (AE)37.440.2

Adverse events

Collected over AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086/saline/Repevax). SAE reported from Vaccination 1 to 6 months after last of investigational product (bivalent rLP2086/saline/Repevax).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: rLP2086 + Repevax—12/374 (3.2%)98/374 (26.2%)
Group 2: Saline+Repevax—9/378 (2.4%)118/378 (31.2%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
AppendicitisInfections and infestations1/3742/378
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders1/3740/378
Vertigo positionalEar and labyrinth disorders1/3740/378
Abdominal abscessInfections and infestations1/3740/378
Appendicitis perforatedInfections and infestations1/3740/378
Arthritis infectiveInfections and infestations1/3740/378
CellulitisInfections and infestations1/3740/378
GastroenteritisInfections and infestations1/3740/378
SinusitisInfections and infestations1/3740/378
TonsillitisInfections and infestations1/3740/378
Most frequent other events
Showing 10 of 20
Most frequent other events
EventGroup 1: rLP2086 + RepevaxGroup 2: Saline+Repevax
NasopharyngitisInfections and infestations30/37431/378
PharyngitisInfections and infestations17/37419/378
Upper respiratory tract infectionInfections and infestations16/37419/378
BronchitisInfections and infestations9/37418/378
GastroenteritisInfections and infestations8/37411/378
HeadacheNervous system disorders9/3749/378
SinusitisInfections and infestations8/3746/378
Otitis mediaInfections and infestations3/3747/378
Acute tonsillitisInfections and infestations1/3747/378
TonsillitisInfections and infestations1/3747/378

Baseline characteristics

Age, Customized
Age, Customized(participants)Group 1: rLP2086 + RepevaxGroup 2: Saline+RepevaxTotal
Greater than or equal (>=)11-less than (<)14years217215432
>=14 years-<19 years156161317
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: rLP2086 + RepevaxGroup 2: Saline+RepevaxTotal
Female183184367
Male190192382
08

Study locations

36 sites
  • Espoo Vaccine Research Clinic
    Espoo, 02100, Finland
  • Helsinki South Vaccine Research Clinic
    Helsinki, 00100, Finland
  • Ita-Helsinki Vaccine Research Clinic
    Helsinki, 00930, Finland
  • Järvenpää Vaccine Research Clinic
    Järvenpää, 04400, Finland
  • Kokkola Vaccine Research Clinic
    Kokkola, 67100, Finland
  • Lahti Vaccine Research Clinic
    Lahti, 15140, Finland
  • Oulu Vaccine Research Clinic
    Oulu, 90220, Finland
  • Pori Vaccine Research Clinic
    Pori, 28100, Finland
  • Seinäjoki Vaccine Research Clinic
    Seinäjoki, 60100, Finland
  • Tampereen Yliopisto University Of Tampere
    Tampere, 33014, Finland
  • Tampere Vaccine Research Clinic
    Tampere, 33100, Finland
  • Vaccine Research Center
    Tampere, FIN-33014, Finland
  • Turku Vaccine Research Clinic
    Turku, 20520, Finland
  • Vantaa Vaccine Research Clinic
    Vantaa, 01300, Finland
  • Gemeinschaftspraxis Dr. med. Guido Hein, Dr. med. Rainer Lauf
    Bad Sobernheim, 55566, Germany
  • Gerhard Bleckmann Kinder- und Jugendarzt
    Baunatal, 34225, Germany
  • Kinderarzt-Praxis
    Bramsche, 49565, Germany
  • Gemeinschaftspraxis fuer Kinder- und Jugendmedizin Dres. Behre, Burgert, Gunkel
    Kehl, 77694, Germany
  • Dr. med. Sobhi Mahdi Kinderarzt und Jugendmedizin
    Luebeck, 23566, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany
  • Dr. Michael Vomstein, Hermann Oesterle, Kinder- und Jugendaerzte
    Schwaebisch-Hall, 74523, Germany
  • Thomas Lenz & (Frau) Dr. med. Marin Eggers
    Vellmar, 34246, Germany
  • Dres.T. Schmitz, H. Knee, Ch, Wittermann Fachaerztliche
    Weilheim, 82362, Germany
  • Gemeinschaftspraxis fuer Kinder und Jugendliche Welzheim
    Welzheim, 73642, Germany
  • Gabinet Lekarski
    Debica, 39-200, Poland
  • Krakowski Szpital Specjalistyczny, im. Jana Pawla II
    Krakow, 31-202, Poland
  • NZOZ Salmed
    Leczna, 21-010, Poland
  • Specjalistyczna Praktyka Lekarska Gravita
    Lodz, 91-347, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Oddzial Pediatryczny
    Lubartow, 21-100, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Eskulap
    Lublin, 20-044, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak
    Oborniki Slaskie, 55-120, Poland
  • Specjalistyczny ZOZ nad Matka i Dzieckiem, Przychodnia Wieku Rozwojowego
    Poznan, 61-825, Poland
  • NZLA Michalkowice Jarosz i Partnerzy
    Siemianowice Slaskie, 41-103, Poland
  • NZOZ Nasz Lekarz
    Torun, 87-100, Poland
  • Szpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny
    Trzebnica, 55-100, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu
    Wroclaw, 50-345, Poland
09

References and documents

Publications

  • Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11. PubMed 35164991 ↗
  • Beeslaar J, Peyrani P, Absalon J, Maguire J, Eiden J, Balmer P, Maansson R, Perez JL. Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infect Dis Ther. 2020 Sep;9(3):625-639. doi: 10.1007/s40121-020-00322-5. Epub 2020 Jul 17. PubMed 32681472 ↗
  • Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23. PubMed 26803328 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Oct 2012, 18 months.

Results were first posted in Nov 2014, 2 years 1 month after primary completion.

Of 13 phase 2 interventional studies under Meningitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2011
First posted
Mar 25, 2011
StartActual
Mar 18, 2011
Primary completionActual
Oct 8, 2012
CompletionActual
Feb 19, 2013
Results first posted
Nov 26, 2014
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01323270
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Mar 18, 2011
Primary completion
Oct 8, 2012
Completion
Feb 19, 2013
Results posted
Nov 26, 2014
Last update
Oct 27, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion